MedInsight Research Institute, Telz Stone, Israel.
Anticancer Res. 2012 Jul;32(7):2471-8.
Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.
曲尼司特（N-[3,4-二甲氧基肉桂酰]-邻氨基苯甲酸；利扎贝特）是一种抗变态反应药物，在日本和韩国获得批准使用，也用于治疗哮喘、自身免疫性疾病以及特应性和纤维变性疾病。曲尼司特的抗肿瘤潜力引起了相当大的关注。本综述总结了有关曲尼司特对不同肿瘤类型影响的最新证据，并讨论了该药在该领域的可能作用模式。涵盖了体内和体外研究，以及临床试验的证据，其中评估了曲尼司特在各种增殖性疾病模型中的作用。本报告中提出的研究结果表明，曲尼司特在管理某些类型的肿瘤方面具有极好的潜力，并为该领域启动对照临床试验提供了强有力的依据。
